![]() Treatment-related discontinuations occurred in 15 pts (13%). Grade 3 or 4 TRAEs occurred in 45 pts (40%) most common (≥5%) were decreased neutrophils (17%) and decreased platelets and lymphocytosis (5%, each). Among all pts with B-cell malignancies treated with nemtabrutinib at the 65-mg dose (N = 112) included in the safety analysis, 82 (73%) had any-grade treatment-related AEs (TRAEs), most common (≥10%) were dysgeusia (21%) decreased neutrophils (20%) fatigue (13%) nausea and decreased platelets (12%, each) and diarrhea and hypertension (10%, each). Efficacy by key subgroups is presented in the table. Among the 32 pts who responded, median DOR was 24.4 months (95% CI, 13.9-not evaluable ) median PFS was 26.3 months (95% CI, 10.1-NE). Among the 24 pts with CLL/SLL who received prior BTKis and BCL-2is, 19 (33%) discontinued, most commonly because of clinical PD and other causes (6 each) and AEs (4 ).Īt data cutoff (April 08, 2022), median (range) follow-up for pts with CLL/SLL was 8.1 months (0.1-38.8) 32 pts had objective response (ORR, 56% complete response, 2 PR, 15 PR with residual lymphocytosis, 15). ![]() Of pts with CLL/SLL, 39 (68%) discontinued, most commonly because of clinical disease progression and "other” causes (10 each) 8 (14%) discontinued owing to adverse events (AEs). Median (range) number of prior therapies was 4 (1-18) 54 pts (95%) had prior BTKi therapy 24 (42%) had prior BTKi and BCL2i therapy. Results: A total of 112 pts were enrolled and were treated with nemtabrutinib 65 mg once daily: 57 had CLL/SLL, 46 had B-cell non-Hodgkin lymphoma (NHL), 6 had Waldenstrom's macroglobulinemia, and 3 had a diagnosis of "other.” Among the 57 pts with CLL/SLL enrolled and treated with nemtabrutinib 65 mg (cohort A, n = 25 cohort B, n = 10 dose escalation, n = 13 cohort I, n = 9) median age was 66.0 years 16 pts (28%) were female, and 50 (88%) had ECOG PS ≤1.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |